UNC2025

News alerts, weekly reports and conference planners

Company:

University of North Carolina-Chapel Hill

Drug class:

FLT3 inhibitor, MERTK inhibitor

NRAS mutation	Melanoma	NRAS mutation	Melanoma	cobimetinib + UNC2025 Sensitive: D – Preclinical cobimetinib + UNC2025 Sensitive : D	cobimetinib + UNC2025 Sensitive: D – Preclinical cobimetinib + UNC2025 Sensitive : D
NRAS mutation	Melanoma	NRAS mutation	Melanoma	UNC2025 Sensitive: D – Preclinical UNC2025 Sensitive : D	UNC2025 Sensitive: D – Preclinical UNC2025 Sensitive : D

Associations
(2)